Home > Publications database > Quality of life after two sequences of total neoadjuvant treatment in patients with locally advanced rectal cancer in the randomized CAO/ARO/AIO-12 phase 2 trial. > print

001     301582
005     20251005022904.0
024 7 _ |a 10.1016/j.ijrobp.2025.05.018
|2 doi
024 7 _ |a pmid:40409541
|2 pmid
024 7 _ |a 0360-3016
|2 ISSN
024 7 _ |a 1879-355X
|2 ISSN
024 7 _ |a altmetric:178263100
|2 altmetric
037 _ _ |a DKFZ-2025-01090
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kosmala, Rebekka
|b 0
245 _ _ |a Quality of life after two sequences of total neoadjuvant treatment in patients with locally advanced rectal cancer in the randomized CAO/ARO/AIO-12 phase 2 trial.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1759150367_1763
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Nov 1;123(3):806-816
520 _ _ |a In a multicenter phase 2 trial the sequence of chemoradiotherapy (CRT) followed by consolidation chemotherapy (CT) prior to total mesorectal excision demonstrated higher pathological complete response rates than induction CT before CRT. Here, we present findings on quality of life (QoL).Patients with rectal carcinoma (cT3-4 cN0-2) were randomly assigned to group A (CT+CRT; N=156) or group B (CRT+CT; N=150). This is a secondary QoL analysis (EORTC QLQ-C30+CR29, Wexner) before and during treatment and of disease-free patients during follow-up.gov identifier: XXXX.At baseline, completed questionnaires were available for 86% (N=134/156; group A) and 89% (N=133/150; group B) of participants, with availability decreasing to 73% versus 64% at 1 year, 61% versus 59% at 2 years, and 51% versus 47% at 3 years. Global health status remained stable in both groups (range 0-100) with baseline scores of 65.2 (mean, SD=21.5; N=133; group A) and 64.7 (SD=23.2; N=131; group B) and with scores of 67.6 (SD=18.4; N=52) and 65.4 (SD=22.2; N=46), respectively, at 3 years. No statistically or clinically relevant differences were observed between groups in any QoL scale upon treatment completion or during follow-up. Both groups experienced declines in role functioning, body image, male impotence, and stool incontinence (Wexner), which did not fully recover over the follow-up period. Rectal blood/mucus discharge and anxiety improved during treatment.QoL did not differ between the two total neoadjuvant treatment sequences. QoL domains with long lasting deterioration may serve as endpoints in future studies focused on organ preservation.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Quality of life
|2 Other
650 _ 7 |a chemoradiotherapy
|2 Other
650 _ 7 |a clinical trial
|2 Other
650 _ 7 |a radiotherapy
|2 Other
650 _ 7 |a rectal neoplasms
|2 Other
700 1 _ |a Hammann, Adriana Salazar
|b 1
700 1 _ |a Paulus, Patrick
|b 2
700 1 _ |a Zimmermann, Marcus
|b 3
700 1 _ |a Wittig-Sauerwein, Andrea
|b 4
700 1 _ |a Germer, Christoph-Thomas
|b 5
700 1 _ |a Ghadimi, Michael
|b 6
700 1 _ |a Hofheinz, Ralf-Dieter
|b 7
700 1 _ |a Diefenhardt, Markus
|b 8
700 1 _ |a Fokas, Emmanouil
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Rödel, Claus
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Polat, Bülent
|b 11
700 1 _ |a Group, German Rectal Cancer Study
|b 12
|e Collaboration Author
773 _ _ |a 10.1016/j.ijrobp.2025.05.018
|g p. S0360301625004833
|0 PERI:(DE-600)1500486-7
|n 3
|p 806-816
|t International journal of radiation oncology, biology, physics
|v 123
|y 2025
|x 0360-3016
909 C O |p VDB
|o oai:inrepo02.dkfz.de:301582
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-31
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-31
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-31
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J RADIAT ONCOL : 2022
|d 2024-12-31
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-31
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-31
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J RADIAT ONCOL : 2022
|d 2024-12-31
920 1 _ |0 I:(DE-He78)FM01-20160331
|k FM01
|l DKTK Koordinierungsstelle Frankfurt
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)FM01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21